Study Type
Interventional - Drug
OCEANIC-STROKE is a multicenter, international, randomized, placebo controlled, double-blind, parallel group, event driven phase 3 study. The study treatment, asundexian, is a new type of anticoagulant that inhibits Factor XI and is currently under development to provide further treatment options and improve the standard of care with regard to the risk of bleeding.
The main purpose of this study is to learn whether adding asundexian to standard therapy reduces the risk of another stroke in participants who recently had a non-cardioembolic ischemic stroke or temporary stroke-like symptoms when given in addition to standard antiplatelet therapy.
Interventional - Drug
Randomized, placebo controlled, double-blind, parallel group, event driven Phase 3 trial
36
717
9300
2023 - 2025
Bayer
Back To Top